BMJ 1998;317:986-990 ( 10 October )

General Practice

Comparison of potency of inhaled beclomethasone and budesonide in New Zealand: retrospective study of computerised general practice records

B D Pethica, research fellow, ^a A Penrose, junior research fellow, ^b D MacKenzie, junior research fellow, ^b J Hall, junior research fellow, ^b R Beasley, professor of medicine, ^a M Tilyard, professor of general practice. ^b

^a Wellington Asthma Research Group, Wellington School of Medicine, University of Otago, Wellington, PO Box 7343, Wellington South, New Zealand, ^b Royal New Zealand College of General Practitioners Research Unit, Department of General Practice, Dunedin School of Medicine, University of Otago, PO Box 913, Dunedin, New Zealand

Correspondence to: Dr Pethica WARG.Sec{at}wnmeds.ac.nz

Objective To determine whether inhaled budesonide and beclomethasone are equipotent in the treatment of asthma in primary care.
Design Retrospective study of computerised clinical records from 28 general practices in New Zealand.
Subjects 5930 patients who received 16 725 prescriptions for inhaled budesonide or beclomethasone from 1 July 1994 to 30 June 1995.
Setting General practices on the database of the Royal New Zealand College of General Practitioners Research Unit. Linked information from secondary care was available for a subset of the practices.
Main outcome measure Mean prescribed daily inhaled corticosteroid dose.
Results The daily prescribed dose was higher for patients receiving inhaled budesonide (mean 979 µg) than beclomethasone (mean 635 µg), a difference of 344 µg (95% confidence interval 313 to 376 µg). This difference was consistent in all age bands and with different types of inhalation device. Evidence of systematic prescribing of higher doses of budesonide to patients with more severe asthma was not found.
Conclusions In primary care in New Zealand evidence suggests that budesonide is less potent than beclomethasone. Consideration of validated, established, and other possible markers of asthma severity did not support confounding by severity as a reason for the higher prescribed doses of budesonide. Pending further epidemiological evaluation, international asthma guidelines may need to be modified on the equivalence of inhaled corticosteroid doses. Furthermore, the comparative potency of newly developed inhaled steroids in clinical trials will need to be confirmed in appropriately designed epidemiological studies based in general practice.

Key messages Important limitations of the randomised clinical trials comparing beclomethasone and budesonide have usually resulted in failure to detect differences in potency In this study using a computerised database in primary care inhaled budesonide had about two thirds of the potency of inhaled beclomethasone Asthma treatment guidelines may need to be modified concerning the dose equivalence of inhaled corticosteroids The relative potency of newly developed inhaled corticosteroids needs to be assessed in primary care

---

© BMJ 1998
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Articles

Comparison of inhaled beclomethasone and budesonide

Christopher Cates, Peter Black, Staffan Edsbäcker, Maria Gerhardsson deVerdier, Christer Hultquist, Samy Suissa, Pierre Ernst, and B D Pethica
BMJ 1999 319: 124. [Extract] [Full Text]

Healthcare rationing: no desistance, no completion
BMJ 1998 317: 0. [Full Text]

Inhaled budesonide may be less potent than beclomethasone in primary care
BMJ 1998 317: 0. [Full Text]

This article has been cited by other articles:

• Green, L. A, Dovey, S. M (2001). Practice based primary care research networks. BMJ 322: 567-568 [Full text]  
• Cates, C., Black, P., Edsbäcker, S., Gerhardsson deVerdier, M., Hultquist, C., Suissa, S., Ernst, P., Pethica, B D (1999). Comparison of inhaled beclomethasone and budesonide. BMJ 319: 124a-124 [Full text]  

Rapid Responses:

Read all Rapid Responses

Patients don't take the prescribed dose of inhaled steroids

C J Cates
bmj.com, 19 Oct 1998 [Full text]

Pitfalls in analysis of inhaled steroid prescribing.

Peter Black
bmj.com, 26 Oct 1998 [Full text]

Analysis has important shortcomings

Staffan Edsbäcker
bmj.com, 5 Nov 1998 [Full text]

Methodological limitations in epidemilogic studies of asthma medication potencies

Samy Suissa
bmj.com, 24 Nov 1998 [Full text]

Response to Dr. Cates Re: Patients don't take the prescribed dose of inhaled steroids

B D Pethica
bmj.com, 4 Feb 1999 [Full text]

Response to Dr. Black Re: Pitfalls in analysis of inhaled steroid prescribing.

B D Pethica
bmj.com, 4 Feb 1999 [Full text]

Response to Dr. Edsbacker Re: Analysis has important shortcomings

B D Pethica
bmj.com, 4 Feb 1999 [Full text]

Response to Prof. Suissa Re: Methodological limitations

B D Pethica
bmj.com, 4 Feb 1999 [Full text]

Further evidence of potency differences between beclomethasone and budesonide?

Alister Penrose
bmj.com, 20 Aug 1999 [Full text]

Online poll

Find out more >>